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Abstract 
Parkinson’s Disease (PD) can be characterised by non-motor symptoms resulting from loss of 
dopamine found in the substantia nigra (SN). Declines in SN’s innervation throughout basal ganglia 
mediates the non-motor symptoms of PD through its feedforward output to the cortex, yet the 
relationship between SN volume loss and subsequent prediction of baseline non-motor symptoms 
and change over time hasn’t been established. Our study aims to address these changes as predicted 
by baseline SN volume at baseline. SN Volumes were gathered by manually tracing the nuclei of 
interest on T2 MRI images and were compared to cognitive/mood data made available through the 
Parkinson’s Progressive Markers Initiative (PPMI). Within a PPMI subset, greater SN Volume loss 
was present at baseline in PD patients compared to controls. Cognitive performance within the 
PPMI subset showed no significant deficits in the PD cohort compared to controls and showed no 
significant deficits between groups over time. Mood dysfunction in the PPMI subset was 
significantly higher in the PD cohort than in controls at baseline and this difference continued over 
time. Linear regressions that controlled for covariables of age, gender and education were run and 
showed that the SN Volume at baseline wasn’t a significant predictor of either longitudinal 
cognitive decline or mood dysfunction. Future work will continue to assess this predictive nature of 
SN volume as this would allow earlier identification for those who are risk of cognitive/mood 
dysfunction, allowing non-therapeutic interventions to alleviate these symptoms and improve 
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Introduction 
Parkinson’s Disease (PD) is a neurodegenerative disease that currently affects around 1 out of 350 
Australians1. With life expectancy continuing to rise, the prevalence of PD is expected to double by 
20302. PD is characterised by cardinal motor symptoms (tremor, rigidity, akinesia or bradykinesia 
and postural instability), the onset of which are necessary for PD diagnosis3,4 , but PD also 
manifests in a number of non-motor symptoms, including cognitive decline and mood dysfunctions, 
which have been consistently reported amongst previous literature5-7. In PD, cognitive decline is 
shown through reduced memory performance and executive functioning ability, which have been 
demonstrated to worsen over time8. Additionally, neuropsychiatric symptoms known as mood 
dysfunctions have been reported in PD, with approximately 30-40% of PD patients having 
significant depressive symptoms9,10 as well as 40% of PD patients showing high rates of 
anxiety11,12. These non-motor symptoms of PD have demonstrated to have important consequences 
for quality of life and daily functioning, as studies have associated the prevalence of these 
symptoms with increased carer burden and increased risk of admission into care homes13. 
 
PD is characterised pathologically by the death of dopaminergic cells (neurons that release the 
neurotransmitter dopamine (DA)) found within the dorsal region of the substantia nigra, known as 
the substantia nigra pars compacta (SNc), a nucleus within the brainstem which plays a critical role 
in the modulation of motor movement14,15 . The reduction of dopaminergic output from the SNc 
affects action selection and inhibition of the basal ganglia, a group of subcortical nuclei responsible 
primarily for motor control and decision making16. The basal ganglia is comprised of two pathways, 
a direct and indirect pathway responsible for the promotion and inhibition of motor activity 
respectively17. In the direct pathway, the dopaminergic projections from the SNc promote the 
activation of the striatum, in turn, inhibiting activation of the globus pallidus internal (GPi) and 
substantia nigra pars reticula (SNr). This decreased inhibitory output from the GPi/SNr feeds 
forward and promotes activation of the thalamus, which promotes cortical activation15,17. 
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Conversely, in the indirect pathway, activation of the striatum feeds forwards to the globus pallidus 
external (GPe) and then to the subthalamic nucleus (STN). Striatal activation in the indirect 
pathway inhibits the external GPe, and this causes disinhibition of the STN due to inhibitory output 
form the GPe to STN. As a result, the STN promotes the release of glutamate on the GPi/SNr, 
driving increased activation of these nuclei, decreasing both thalamic and cortical activation, 
inhibiting motor movement 16,17. In the indirect pathway, striatal output is impacted directly by the 
DA input from the SNc and can be seen in Figure 1. Information from the basal ganglia is relayed 
from the output nuclei, GPi/SNr, to various cortical areas, including the primary motor cortex and 
the prefrontal cortex (PFC)18. 
 
Figure 1: A schematic diagram showing the circuitry of the basal ganglia and how the indirect 
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As PD is pathologically characterised by a loss of DA in the SNc, dopaminergic depletion leads to 
reduced inhibitory direct pathway output, and increased excitatory indirect pathway output onto the 
GPi/SNr, resulting in greater thalamic and cortical inhibition (Figure 1)19. This DA loss in PD can 
also affect the cognitive and mood symptoms due the feedforward connections from the basal 
ganglia to the cortex and limbic system20. Specifically, in studies that assessed the cortical co-
activation on functional neuroimaging, specific cortical regions were displayed to have received 
feedforward communication from the basal ganglia, including primary and supplementary motor 
cortices, the dorso-lateral prefrontal cortex (PFC) (decision making), the amygdala (emotional 
regulation) and the hippocampus (memory)18. Loss of input to these specific cortical areas highlight 
the prevalence of the non-motor symptoms of PD, namely the PFC for the cognitive decline and 
amygdala for the mood dysfunctions that have been reported in prior literature5-12. As the basal 
ganglia is mediated via DA input, this loss of DA in PD could explain the onset of these non-motor 
symptoms. 
 
As evident from prior literature, DA input facilitates the activation of cortical areas responsible for 
cognitive functioning21,22. Anatomically, the PFC contains a large number of DA receptors and is 
highly sensitive to DA binding23. Due to the anatomical distribution of the brainstem DA projection 
towards the PFC as well as the GABAergic input from the dorso-lateral striatum within the basal 
ganglia, this provides a basis for DA’s influence on working memory and executive decision 
making, explaining how decreased DA levels in PD may be associated with decreased memory 
performance23,24 and demonstrates that normal levels of DA appear necessary for optimal cognitive 
performance24-27.  
. 
Previous findings have also highlighted that dopamine has implications for the regulation of mood 
28,29. Studies have shown that DA loss is a factor of mood dysfunctions seen in individuals30-32. In 
studies of depression and anxiety, PET imaging studies have shown significantly lower DA 
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transporter binding and striatal activation compared with healthy subjects27. Moreover, a PET study 
demonstrated that PD patients who showed increased levels of anxiety and depression after 
receiving deep brain stimulation, a surgical treatment for PD, expressed a greater cortico-limbic 
dopaminergic denervation than patients who do not33. Anatomically, the amygdala is highly 
innervated by DA projections for activation regulation, as well as convergent fibres from the ventral 
striatum, which could explain why loss of DA in PD is accompanied by mood dysregulation and 
overall dysfunction20,34. These findings highlight the importance of monitoring DA levels in PD 
patients, as these levels may be indicative of decline in cognitive and increase of mood dysfunctions 
seen in PD.  
 
Currently, assessing the levels of DA is difficult in vivo, which, in turn, makes predicting the onset 
of the non-motor symptoms of PD rather challenging. Although PET imaging of dopaminergic 
markers has improved in recent years35 it is prohibitively expensive, not widely available and 
requires the use of invasive radioactive tracers36. Thus, it has been suggested that SN Volume, as 
measured by T2 MRI, could be a proxy marker of DA loss, as with greater signal loss in the SN, 
indicating volume loss, which in turn indicates loss of DA neurons. 
 
To date, the relationship between the volume of the SN and cognitive and mood symptoms of PD, 
particularly how predictive baseline SN volume is of the change over time in these non-motor 
symptoms, has not been established. Establishing this relationship may aid in the strengthening the 
prognosis of the non-motor symptoms in PD and their trajectory from a single, baseline 
measurement. 
 
Thus, this study aims to assess whether baseline measures of SN volume, cognitive function and 
mood differ between the PD cohort and those in the control group and investigate the trajectory of 
change in cognition/mood over a 5-year period. It is hypothesised that cognition function and mood 
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will be negatively over time as a result of volume loss in the SN, predicted through DA loss in the 
SN, measured via SN volume. Understanding this relationship is significant as it could lead towards 
the improvements in predicting the trajectory of these non-motor symptoms in PD, allowing earlier 
identification for those who are risk of cognitive/mood dysfunction, allowing non-therapeutic 






















Adelaide Medical School 9 
Methodology  
Data Extraction 
Participants for the current study were drawn from the Parkinson’s Progressive Markers Initiative 
(PPMI) database37 and consisted of 69 PD patients and 34 controls who at the time of PD diagnosis 
(or recruitment for the control cohort) underwent baseline T2 MRI scans. Participants in the control 
cohort were all above the age of 30 years on and had no first degree relative with PD37.  Collection 
of the data was originally conducted in accordance with the Declaration of Helsinki and the Good 
Clinical Practice (GCP) guidelines and was approved by the local ethics committees of each of the 
participating sites. For the current word, access to this data was provided through application37. The 
PPMI database contains data for a number of cognitive performance and mood measures, which 
were taken at baseline (time of diagnosis or recruitment), as well as annually for a 5-year period. 
The specific cognitive and mood measures are displayed in Table 1. 
 




Name of Measure Aspect of cognition/mood measured 
Hopkins Verbal Learning Test (HVLT) Assessment of verbal learning and memory (recognition 
and recall)38 
Letter Number Sequencing (LNSPD) Assess incremental demand of working memory39 
 
Sematic Fluency (SFT) Determine sematic fluency by measuring production of 
words to fit a given category40 
Geriatric Depression Scale (GDS) Assessment of depressive symptoms in an older adult 
population 
 
State Trait Anxiety Index (STAI) Describes trait levels of Anxiety 
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For the analysis of the cognitive/mood data, the scores from the three cognitive tests that the 
participants completed annually were summed into a singular score that captured the overall 
cognitive performance of the participants at each time point. This was done by converting the test 
scores from each cognitive test to z-scores and these z-scores were averaged to form a single 
‘cognitive beta-score’. The use of this combined cognitive score was a good representative of 
general cognitive performance. A systematic review in 2012 reported that testing overall 
performance is enhanced by utilizing measures that assess attention span, recognition and recall and 
verbal fluency, and these aspects were of cognition were tested between the HVLT, LNSPD and 
SFT measures41. In parallel with the cognitive data, mood test results were also converted to z-
scores and averaged, to form a ‘mood beta-score’. The use of this combined mood score gives a 
good overall measurement of neuropsychiatric function, as previous DA-mediated findings have 
been linked to the prevalence of depression and anxiety in individuals, which have been assessed 
through the GDS and STAI42. 
 
Mapping the volumes of Brainstem Nuclei 
For all PPMI subjects, a non-contrast enhanced T2 weighted brain MRI using at least 1.5 Tesla 
scanner and a non-contrast enhanced 3D volumetric T1 weighted brain MRI were performed at 
baseline. T1 weighted images were acquired with the MPRAGE sequence with parameters 
including: slice thickness of <1.5mm with no interslice gap, voxel size = 1 x 1 x 1.2mm3 and 
acquired matrix size = 256 x 256 x 170-200 37. Using an imaging program ‘FSLeyes’, blank overlay 
masks were created on top of these T2 weighted MRI scans. After selecting the most appropriate 
horizontal slice and contrast and brightness of the brainstem that optimised the view of the nuclei, 
masks were edited by manually tracing the SN, the Red Nucleus (RN), as well as the overall 
midbrain itself, and these tracings were filled into the masks (Figure 2). The SN, RN and midbrain 
were chosen for mapping as this would allow a series of nuclei ratios to be created, namely SN:RN 
and SN:midbrain. As opposed to using the SN signal on its own, these ratios allowed for individual 
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differences between each participant to be accounted for. In addition, the RN was chosen for 
mapping as the A10 dopaminergic projections from the RN are spared in PD43-46 , even though the 
RN physically neighbours the SN.  
 
A total of 619 subjects (423 PD and 196 healthy controls) are included in the baseline PPMI 
dataset37. However, for the current analysis, MRI scans from a subset of 103 particpiants (69 
patients and 34 controls) were selected for analysis. This subset was chosen as all participants had 





Due to the nature of manual tracing of the midbrain nuclei, these measurements can be quite 
subjective across different raters. In order to maximise the reliability of the traced masks, the masks 
were created individually by two raters and were compared. The inter-rater reliability was 
calculated and, in cases of extreme variance between the raters (where voxel difference > 30), 
specific cases were re-mapped independently and corrected (SN:midbrain -  r = 0.712, SN:RN - r = 
0.435. As the correlation coefficient of the SN:midbrain ratio was much stronger than the SN:RN 
B A 
Figure 2: Manual mask creating mapping of the brainstem’s nuclei.  
A. T2 weighted MRI of the brainstem B. The same T2 MRI with the following regions mapped: midbrain 
(yellow), red nuclei (red) and the substantia nigra (green). 
The 
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Given the high correlation between the SN:midbrain data, scores were averaged between the raters. 
To analyse the baseline SN volume loss between the two groups, a Welch two samples t-test was 
conducted. To investigate the cognitive and mood trajectories, multiple regression models were run 
to test whether group membership predicted baseline cognitive function and mood, and the rate of 
change seen over a 5-year time period. To assess the predictive nature of SN volume on 
cognitive/mood performance, linear regressions were executed to analyse how influential the SN 
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Results 
PPMI Data Demographics: Cognitive and Mood Dataset 
Demographic information for both PD patients and healthy controls for the entire PPMI database is 
reported in Table 2. The groups were similar with regards to age, gender and years of education 
(table 2). 
Table 2: Subject demographics of PD patients and healthy controls 
 
 
PD patients Healthy Controls 
  
 
N Mean ± SD N Mean ± SD t-Test (df)    P 
       
Age (years) 423 (61.66 ± 10.17) 196 (60.82 ± 10.19) -0.91(335) .364 
Education (years) 423 (15.60 ± 3.05) 196  (16.04 ± 3.05) 1.92(389) .055 
Gender 423  196  0.29 (377) 0.772 
Males 146         23.60% 70         35.71% 
  
Females 277         44.75% 126         64.29% 
  
 
Note: Within the PPMI Database, gender was coded as “1 = Male’ and “2 = Female” after being 
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PPMI Imaging Subset Demographics: Cognitive and Mood Dataset 
Demographic information for both PD patients and healthy controls within the subset of PPMI 
participants used for the imaging subset is reported in Table 3. The groups were similar with 
regards to age, gender and rates of education (table 3). 
 
Table 3: Subject demographics of PD patients and healthy controls within the Subset 
 
 
PD patients Healthy Controls 
  
 
N Mean ± SD N Mean ± SD t-Test (df)    P 
       
Age (years) 69 (61.42 ± 9.47) 34 (59.65± 11.56) -0.77 (55) 0.443 
Education (years) 69 (16.45 ± 2.21) 34  (16.76 ± 2.47) 0.63 (59) 0.53 
Gender 103  103  -0.24 (66) 0.81 
Males 45         65.22% 23         67.65% 
  
Females 24         34.78% 11         32.35% 
  
 
Note: Within the PPMI Database, gender was coded as “1 = Male’ and “2 = Female” after being 
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Cognitive and Mood Trajectory within the Full Dataset 
Within the full PPMI dataset, cognitive performance was significantly lower in PD patients than in 
controls at baseline (t(1,359) = -4.151, p < 0.001) and significantly decreased over time after 
controlling for age, gender and education (coefficient = -0.278, t(4, 551) = -3.381, p < 0.001) 
 (figure 3). 
Figure 3: Cognitive performance in PD was lower than that of controls at baseline ( p < 0.001) and 
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Within the full dataset, mood dysfunction was significantly higher in PD than in controls at baseline 
(t(1,425) = 6.267, p < 0.001)  and increased over time at significantly faster rate in PD compared to 
controls after controlling for age, gender and education (coefficient = .489, t(4, 553) = 5.537, p < 
0.001) (figure 4). 
Figure 4: Mood dysfunction in PD was greater than that of controls at baseline (p < 0.001) and 
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Cognitive and Mood Trajectory for Imaging Subset  
Given that MRI scans were only available on a restricted portion of the sample, the above analyses 
were repeated within the 103 participants that had both MRI scans and cognitive/mood data. Within 
this sample, the SN:Midbrain ratio was significantly higher in PD patients than in controls [(t) = -
6.05, p < 0.001], indicating greater MRI signal loss, and, in turn, greater SN volume loss, in the PD 
group (figure 5). 
 
Figure 5: SN/midbrain ratio comparison between groups. The SN/midbrain ratio of the Control 
group (dark blue) was significantly lower than the patient group (light blue) (p < 0.001).  
*** 
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Within the imaging sample, cognitive performance did not significanty differ between PD patients 
and controls (t(1,53) = 1.09; p = 0.27) at baseline. Similarly, change in cognitive function over the 
5-year period did not differ in PD patients compared to healthy controls after controlling for age, 
gender and education (coefficient = 0.065, t(4, 84) = 1.56, p = 0.33) (figure 6).  
 
Figure 6: Cognitive performance in PD showed no statistical difference to that in the control group 
at baseline (p = 0.27) and did not differ significantly over time in PD patients compared to controls 
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In the subset of participants who had MRIs, mood dysfunction was significantly higher in PD than 
in healthy controls at baseline (t (1,81) = -2.21, p = 0.029). Over time, the rate of change in mood 
dysfunction continued to be significantly greater in PD patients than in healthy controls after 
controlling for age, gender and education (coefficient = 0.069, t(4, 84) = -0.776, p = 0.28) (figure 
7). 
 
Figure 7: Mood dysfunction in PD was greater than that of controls at baseline (p = 0.029) but did 
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Ability of SN volume to predict baseline cognitive performance/mood dysfunction and change 
over time 
The regression coefficients for the ability of SN:midbrain to predict baseline cognitive 
performance/mood dysfunction, as well as change over time, are reported in the tables below, along 
with relevant covariates.  Table 4 assessed baseline measurement, whereas table 5 utilised the ‘beta 
score’. 
 
Table 4: Baseline regression coefficients and their accompanying statistical test results for the 
proposed covariables on cognitive and mood outcomes.  
 N R2 F Statistic (df) Slope Coefficient T Statistic P -Value 
Baseline Cognitive 
Performance 
90 0.19 5.637 (5,90)   <0.001 
Age    -0.02 -2.43 * 
Gender    0.48 2.85 ** 
Education    0.11 3.12 ** 
Diagnosis    -0.30 -1.47 / 
SN:Midbrain    4.59 1.08 / 
Baseline Mood 
Dysfunction 
90 0.045 1.903 (5,90)   0.10 
Age    -0.015 -1.58 / 
Gender    0.04 0.25 / 
Education    -0.03 -0.92 / 
Diagnosis    0.30 1.29 / 
SN:Midbrain    3.51 0.72 / 
Note:  / = ‘no significance between groups’, “*” 0.05, “**”  0.01. 
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Table 5: Longitudinal regression coefficients and their accompanying statistical test results for 
the proposed covariables on cognitive and mood outcomes. 
 N R2 F Statistic (df) Slope Coefficient T Statistic P -Value 
Beta Cognitive Performance 84 0.0095 1.171 (5,84)   0.33 
Age    -0.018 -2.07 * 
Gender    0.12 0.66 / 
Education    0.017 0.45 / 
Diagnosis    0.18 0.86 / 
SN:Midbrain    -6.76 -1.56 / 
Beta Mood Dysfunction 84 0.014 1.259 (5,84)   0.29 
Age    0.011 1.32 / 
Gender    -0.011 -0.07 / 
Education    -0.0067 -0.19 / 
Diagnosis    0.36 1.85 / 
SN:Midbrain    -3.079 -0.78 / 
Note:  / = ‘no significance between groups’,“*” 0.05,  
 
Results of the multiple linear regressions indicated that at baseline, there was a collective significant 
effect between the covariables and cognitive performance (F(5,90) = 5.637, R2 = .19, p <.001), 
however, there was no significant effect on mood dysfunction ( p = 0.1). The individual predictors 
of baseline cognition were examined further and indicated that age (t = -2.43, p =.05), gender 
(t=2.85, p = .01) and education (t=3.12, p = .01) were significant predictors in this model. Results 
of the multiple linear regressions of the change in scores over time indicated that there was no 
collective significant effect between the covariables and cognitive performance (p =.33) and mood 
dysfunction ( p = .29). Examining the individual predictors of beta cognition further, it was 
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indicated that age (t = -2.07, p = 0.05) was the only significant predictor in this model. Apart from 
this, no other variables were significant predictors of change in cognition or mood over time.  
 
In the above regression models, the whole dataset was used, with diagnosis included as a covariate. 
In order to probe the effect of diagnosis on the predictive value of the SN:midbrain ratio, a linear 
regression was also run in just the PD group, with age, gender and years of education included as 
covariates (Tables 6 and 7). These regressions were additionally run in just the control cohort 
(Tables 8 and 9). Full tables of all regression model output in the specific cohorts can be found in 
the appendix. 
 
Results of the multiple linear regressions in the PD group indicated that at baseline, there was a 
collective significant effect between the covariables and cognitive performance (F(4,59) = 9.316, 
R2 = .35, p <.001), however, there was no significant on mood dysfunction (p = .93). The 
individual predictors of baseline cognition were examined further and indicated that age (t = -3.79, 
p =.001), gender (t=2.33, p = .05) and the SN:midbrain ratio (t= 2.41, p = .05) were significant 
predictors in this model. Results of the multiple linear regressions of the change in scores over time 
in PD indicated that there was no collective significant effect between the covariables and cognitive 
performance (p =.088) and mood dysfunction (p = .73). Examining the individual predictors of beta 
cognition further, it was indicated that age (t = -2.22, p = 0.05) was the only significant predictor in 
this model. Apart from this, no other variables were significant predictors of change in cognition or 
mood over time.  
 
Results of the multiple linear regressions in the control group indicated that at baseline, there was a 
collective significant effect between the covariables and mood dysfunction (F(4,27) = 7.639, R2 = 
.46, p <.001), however, there was no significant on cognitive performance (p = .327). The 
individual predictors of baseline mood dysfunction were examined further and indicated that 
education (t = -3.09, p =.01) and the SN:midbrain ratio (t= 3.06, p = .01) were significant 
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predictors in this model. Results of the multiple linear regressions of the change in scores over time 
in the control group indicated that there was no collective significant effect between the covariables 
and cognitive performance (p =.15) and mood dysfunction (p = .68). In these models no variables 
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Discussion 
The study aimed to investigate the predictive nature of the SN volume on the longitudinal non-
motor symptoms of PD, assessed by highlighting difference in the non-motor symptoms between 
the PD group and healthy controls and investigated if these differences could be predicted by SN 
volumes. In the overall PPMI dataset, cognitive performance was lower in PD than in controls and 
rates of mood dysfunction in PD were greater than the control and results remain similar with 
change over time. Within the PPMI subset, baseline cognitive performance showed no difference 
between groups, however baseline mood dysfunctions were greater in PD compared to control. 
Over time, cognitive performance and mood dysfunction within the PPMI subset showed no 
significant differences. After executing regression models, the SN volume was only a significant 
predictor of baseline cognition in the PD group and baseline mood dysfunction in the control group. 
Beyond this, the SN volume overall was not a significant predictor of the longitudinal non-motor 
symptoms of PD. 
 
In the PPMI subset, cognitive performance did not differ between the two groups at baseline and 
over time. These results were not hypothesized and are inconsistent with literature, which 
demonstrated significant cognitive decline in PD compared to controls47,48. This discrepancy may 
be accounted for by the small number of subjects in the subset. The results showed that among the 
total PPMI cohort, cognition differs between groups, however, the subset didn’t reflect this, 
suggesting this subset wasn’t a good representation of the overall data. Future work may wish to try 
and capture this representation in a better way. Literature shows that visuospatial and executive 
functioning aspects of cognition are more likely to show changes in PD49 and deficit in memory and 
language aren’t often reported50. This could be probed further in future by utilizing tests that assess 
these specific domains of cognition and ultimately, the utilisation of a single cognition score wasn’t 
ideal and may explain why we saw these results.  
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The PPMI subset also demonstrated baseline differences in mood dysfunction between PD and 
control groups. Higher mood dysfunctions in PD than in controls has been reported throughout 
literature and our results are consistent with these findings51. According to the Braak hypothesis, 
there is a caudal to rostral spread of DA loss pathology from the brainstem to the cortex in early 
PD52. This suggests that pathology within brainstem nuclei, such as the amygdala (responsible for 
emotional regulation) is more prevalent in early PD than that of areas responsible for cognition 
(pre-frontal cortex). This provides explanation to why we saw baseline differences in mood, but not 
in cognition in the PPMI subset. Furthermore, previous findings have highlight that the prevalence 
of depressive symptoms in PD is significantly greater than all other psychiatric disorders53. 
Therefore, the use of the single mood score scores may not have been a good representation over 
overall mood dysfunction, and future work may need to be investigate levels of depression 
independently to better capture the mood dysfunctions of PD. 
 
 
The SN/midbrain ratio of the control group was significantly lower than the patient group. This 
greater ratio in the PD group indicates greater signal loss of DA on MRI, and in turn, reflects 
greater loss in SN volume. These results validate this methodology of assessing SN integrity as a 
means of comparing differences between PD patients and healthy controls, however, future work 
could further strength the capturing of SN volume with the use of correlating volumes to DaTScans, 
single-photon emission computed tomography (SPECT) imaging technique that helps visualize 
dopamine transporter levels in the brain54, whose data was available through the PPMI. 
 
As opposed to what was hypothesised, after running the linear models for both baseline and 
longitudinal cognitive/mood data in the PPMI subset, SN:midbrain was not a significant predictor. 
Additionally, besides for predicting baseline cognitive performance, there was no significant 
evidence showing that the overall linear models significantly predicted the outcomes through the 
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influence of the covariables. Though the SN:midbrain was not a significant predictor of cognitive 
and mood performance, it was the most influential covariable at baseline and longitudinally.  
 
All four regression models displayed adjusted R2 values that showed that less than 20% of the 
variance (at best) in cognitive/mood data in all cases could be explained by the covariables, 
indicating that the models didn’t sufficiently fit the data. This could be improved by increasing to 
sample size of the subset or through controlling for specific covariables. Linear regressions models 
were refined and repeated to only account for those each cohort respectively within the PPMI 
subset. 
 
Looking at the cognitive regressions, SN:midbrain ratio was a significant predictor of baseline 
cognition, but not of the change over time only within the PD cohort only and not of the controls. 
This indicates that real time SN volumes (as they were taken at baseline) were able to predict the 
cognitive performance in PD patients at the time of their cognitive testing. This highlights a 
weakness to this study, as the MRIs were only taken at baseline, unlike the cognitive tests which 
were executed annually. The baseline SN:midbrain ratio wasn’t predictive of the change in 
cognition over time and may need to be further investigated with annual MRIs to assess how SN 
volumes changed with respect to changes in cognition. Focusing on the mood regressions of the 
control group only, SN:midbrain ratio was a significant predictor of baseline mood dysfunction, in 
the control group. However, this was not the same within the PD group. This suggests that the 
SN:midbrain ratio was not a good predictor of mood dysfunctions in PD at baseline, nor the change 
over time.  
 
Our results suggest that the changes in cognition and mood could better explained by other factors. 
Literature has stated that the time-of-day appears to affect cognitive performance of older patients 
who have suffered a neurological defect (minor stroke)55 and has also found that age is the biggest 
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risk for cognitive decline and difficulty with mood regulation56. These findings can be seen 
throughout our results which show that the age was the most significant predictor of these non-
motor changes over time compared to all other covariables, including the SN:midbrain ratio. This 
highlights a number of factors besides SN volumes that may better predict cognitive performance 
and mood dysfunction and future work may seek to assess their predictive nature of the change in 
cognition and mood over time. 
 
As highlighted throughout, non-motor symptoms are highly prevalent in PD and have demonstrated 
to have a number of factors that decrease the overall quality of life of PD patients. It is of 
continuing importance to predict the onset and trajectory of these non-motor symptoms of PD and 
our results show that the volume of SN may have selective benefits in predicting the cognitive 
performance and mood dysfunction at baseline, future work will continue to be predict this 
trajectory.  
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Appendix 
 
Table 6: Baseline regression coefficients and their accompanying statistical test results for the 
proposed covariables on cognitive and mood outcomes in the PD Group 
 N R2 F Statistic (df) Slope Coefficient T statistic P -Value 
Baseline Cognitive 
Performance 
59 0.35 9.316 (4,59)   < 0.001 
Age    -0.04 -3.79 *** 
Gender    0.5 2.33 * 
Education    0.056 1.23 / 
SN:Midbrain    13.29 2.41 * 
Baseline Mood 
Dysfunction 
59 0.05 0.217 (4,59)   0.93 
Age    -0.012 -0.77 / 
Gender    0.052 0.19 / 
Education    0.023 0.39 / 
SN:Midbrain    -2.7 -0.39 / 
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Table 7: Longitudinal regression coefficients and their accompanying statistical test results for 
the proposed covariables on cognitive and mood outcomes in the PD group. 
 N R2 F Statistic (df) Slope Coefficient T Statistic P -Value 
Beta Cognitive 
Performance 
55 0.071 2.136 (4,55)   0.088 
Age    -0.03 -2.22 * 
Gender    0.077 -0.29 / 
Education    -0.111 -1.81 / 
SN:Midbrain    -3.427 -0.53 / 
Beta Mood 
Dysfunction 
55 0.03 0.496 (4,55)   0.73 
Age    0.018 1.21 / 
Gender    -0.008 -0.029 / 
Education    -0.019 -0.28 / 
SN:Midbrain    -2.70 -0.38 / 
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Table 8: Baseline regression coefficients and their accompanying statistical test results for the 
proposed covariables on cognitive and mood outcomes in the Control Group 
 N R2 F Statistic (df) Slope Coefficient T statistic P -Value 
Baseline Cognitive 
Performance 
27 0.028 1.229 (4,27)   0.327 
Age    -0.012 -0.62 / 
Gender    0.47 1.21 / 
Education    0.16 1.97 / 
SN:Midbrain    -2.41 -0.26 / 
Baseline Mood 
Dysfunction 
27 0.46 7.639 (4,27)   <0.001 
Age    -0.006 -0.44 / 
Gender    0.094 0.32 / 
Education    -0.18 -3.09 ** 
SN:Midbrain    21.5 3.06 ** 
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Table 9: Longitudinal regression coefficients and their accompanying statistical test results for 
the proposed covariables on cognitive and mood outcomes in the Control group. 
 N R2 F Statistic (df) Slope Coefficient T Statistic P -Value 
Beta Cognitive 
Performance 
25 0.10 1.811 (4,25)   0.15 
Age    -0.038 -1.96 / 
Gender    0.56 1.46 / 
Education    0.18 2.23 / 
SN:Midbrain    -10.5 -1.14 / 
Beta Mood Dysfunction 25 0.06 0.57 (4,25)   0.68 
Age    0.0012 0.066 / 
Gender    0.11 0.28 / 
Education    0.047 0.58 / 
SN:Midbrain    -10.7 -1.14 / 
Note:  / = ‘no significance between groups’ 
 
